Revolution Medicines/$RVMD

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Ticker

$RVMD
Primary listing

Industry

Biotechnology

Employees

616

ISIN

US76155X1000

RVMD Metrics

BasicAdvanced
$7.4B
-
-$4.02
1.11
-

What the Analysts think about RVMD

Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
0.00%50.00%100.00%JulAugSeptOctNovDecJanFebMarAprMayJun

Bulls say / Bears say

Revolution Medicines' RAS(ON) inhibitor, zoldonrasib, demonstrated a 61% objective response rate and an 89% disease control rate in non-small cell lung cancer patients at 1200 mg QD, indicating strong clinical efficacy. (stockanalysis.com)
The company successfully closed an upsized public offering, raising $862.5 million, which strengthens its financial position to advance its oncology pipeline. (barchart.com)
Analysts maintain a 'Strong Buy' consensus with a 12-month average price target of $68.75, suggesting a potential upside of approximately 70%. (stockanalysis.com)
Shares of Revolution Medicines dropped approximately 31% pre-market after presenting data from Phase 1/1b studies for its RAS(ON) inhibitor RMC-6236, raising concerns about the drug's market reception. (seekingalpha.com)
Insider selling activity, including CFO Jack Anders selling 2,635 shares, may signal potential concerns about the company's near-term prospects. (techdows.com)
Despite positive analyst ratings, the stock has experienced volatility, with a notable decline of 7% over a four-week period, indicating potential market skepticism. (wallstrank.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

RVMD Financial Performance

$0$20B$40B$60BQ4 23Q1 24Q2 24Q3 24
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RVMD Earnings Performance

$0.00$2.00Q4 23BeatQ1 24BeatQ2 24BeatQ3 24BeatQ4 24-
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RVMD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs

Can we use optional cookies? View our Cookie Policy for details.

pixel